Luxottica Group S.p.A Stock Hits New 52-Week High (LUX)

NEW YORK ( TheStreet) -- Luxottica Group S.p.A (NYSE: LUX) hit a new 52-week high Wednesday as it traded at $32.47 compared with its previous 52-Week high of $32.19. Luxottica Group S.p.A is changing hands at $32.30 with 73,723 shares traded as of 10:01 a.m. ET. Average volume has been 112,100 shares over the past 30 days.

Luxottica Group S.p.A has a market cap of $14.6 billion and is part of the services sector and specialty retail industry. Shares are up 4.3% year to date as of the close of trading on Tuesday.

Luxottica Group S.p.A. and its subsidiaries design, manufacture, and distribute luxury, fashion, and sport/performance eyewear worldwide. It operates in two segments: Manufacturing and Wholesale Distribution, and Retail Distribution. The company has a P/E ratio of 27.9, below the average specialty retail industry P/E ratio of 28.5 and above the S&P 500 P/E ratio of 17.3.

TheStreet Ratings rates Luxottica Group S.p.A as a buy. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth, expanding profit margins, solid stock price performance and largely solid financial position with reasonable debt levels by most measures. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. You can view the full Luxottica Group S.p.A Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing